Displaying 81 - 100 of 853
| Active Ingredient | ETHAMBUTOL |
| Therapeutic Class | ANTITUBERCULOSIS AGENTS |
| Indications | Tuberculosis, in combination with other drugs. |
| Caution | Optic neuritis. Use with caution in renal disease, and in the elderly . Avoid in children under 6 years. Visual acuity and red-green colour discrimination occurs at doses of 25mg/kg. May cause G.I. u More ... |
| Dose Range | Adult: 15 mg/kg/day as a single dose, alternatively, three times weekly (25 to 30 mg/kg/dose) or twice weekly (50 mg/kg/dose) dosing has been given; patients with renal insufficiency require dosage adjustment. Pediatric: 15-20mg/kg/day.Take with food. |
| Drug Interactions | |
| Pregnancy | The manufacturer states that ethambutol should be used during pregnancy only whe More ... |
| Breast Feeding |
| Active Ingredient | ISONIAZID |
| Therapeutic Class | ANTITUBERCULOSIS AGENTS |
| Indications | Tuberculosis, in combination with other drugs |
| Caution | Peripheral neuritis (treat with 50-100mg pyridoxine daily). Hepatitis (like viral hepatitis) convulsions, optic neuritis with atrophy . Monitor SGOT, SGPT, (if symptomatic) Albumin phosphatase. Avoid More ... |
| Dose Range |
Adult: 300mg (5mg/kg/day ) daily in a single dose. May also be given as 900mg (15mg/kg) twice weekly as a single dose. Pediatric: 10mg/kg daily. Take on empty stomach. May be taken with food to avoid upset stomach. |
| Drug Interactions | |
| Pregnancy | Category: C Use with caution if benefits outweigh risks. Animal studies show ris More ... |
| Breast Feeding | Distributed into milk but safe for nursing infants |
| Active Ingredient | PYRAZINAMIDE |
| Therapeutic Class | ANTITUBERCULOSIS AGENTS |
| Indications | Tuberculosis as a second line drug in combination with other drugs. |
| Caution | Hyperuricemia, acute gout, hepatotoxicity, G.I. upset. Diabetes mellitus becomes more difficult to manage. Monitor SGOT, SGPT and uric acid levels. Give intermittently to avoid hypercalcaemia. |
| Dose Range | 15-30 mg/kg/day up to a max.of 2 g daily ; or 50-70 mg/kg 2-3 times weekly. Tuberculosis in AIDS p atients, doses of 20 to 30mg/kg/day have been successful. Dosage reduction is recommended in patients with endstage renal disease. Take with food to avoid |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | Because pyrazinamide is distributed into milk in small amounts, a decision shoul More ... |
| Active Ingredient | RIFAMPICIN |
| Therapeutic Class | ANTITUBERCULOSIS AGENTS |
| Indications | Tuberculosis, in combination with other drugs. |
| Caution | Orange coloured urine, tears and saliva. Flu-like syndrome, hepatitis, thrombocytopenia, hemolysis, renal failure. Monitor SGOT, SGPT levels and discontinue if levels are more than twice normal. More ... |
| Dose Range |
Adult: 600mg/day . Pediatric: 10-20mg/kg/day, up to a maximum of 600 mg/day. The duration of therapy varies with the infection or condition being treated. Dosage adjustments should be considered in patients with liver disease. Take at least 30 minutes |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CLOFAZIMINE |
| Therapeutic Class | ANTIMYCOBACTERIALS, MISCELLANEOUS |
| Indications | Leprosy.Indicated for treatment of lepromatous leprosy, including dapsone-resistant leprosy complicated by erythema nodosum leprosum |
| Caution |
Preferably used in combination with 1 or more other antileprosy agents to prevent the emergence of drug resistance. Skin discoloration may occur. Gastrointestinal: Abdominal and epigastric pain, dia More ... |
| Dose Range |
Dapsone-resistant leprosy 100mg daily with food.combination with 1 or more other antileprosy drugs for 3 years, followed by monotherapy with 100 mg of clofazimine daily. Dapsone-sensitive multibacillary leprosy 50 mg PO qDay in combination with dapsone |
| Drug Interactions | |
| Pregnancy | Use with caution. |
| Breast Feeding | May alter colour of breastmilk and cause skin discoloration in neonates. |
| Active Ingredient | DAPSONE |
| Therapeutic Class | ANTIMYCOBACTERIALS, MISCELLANEOUS |
| Indications | For the treatment of Leprosy. |
| Caution |
Hemolytic anemia, methemo-globinemia, aplastic anemia, psychoticn episodes, hepatotoxicity , nephrotic syndrome. May cause dizziness. Exercise caution when driving or operating machinery . Dapsone More ... |
| Dose Range | 100mg once daily. |
| Drug Interactions | |
| Pregnancy | Folic acid (higher dose) should be given to mother throughout pregnancy; neonata More ... |
| Breast Feeding | Dapsone is distributed into breast milk but in small amounts. A decision should More ... |
| Active Ingredient | ANTIVIRALS |
| Therapeutic Class | ANTIVIRALS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AMANTADINE |
| Therapeutic Class | ADAMANTANES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ANTIRETROVIRALS |
| Therapeutic Class | ANTIRETROVIRALS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ATAZANAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications | HIV-1 infection in treatment -naïve and treatment-experienced adults and pediatric patients 6 years of age or older. |
| Caution | Rash, abdominal pain, diarrhoea, nausea, unconjugated hyper- bilirubinemia, headache, lactic acidosis. |
| Dose Range | Adult: Atazanavir 300mg/ ritonavir 100mg once daily with food. |
| Drug Interactions | |
| Pregnancy | Theoretical risk of hyperbilirubinaemia in neonate if used at term. |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | DARUNAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | RITONAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications |
Not typically used as sole protease inhibitor (PI), but as pharmacokinetic enhancer of other PIs Indicated in combination with other antiretroviral agents for the treatment of HIV-infection See lopin More ... |
| Caution | See lopinavir/ritonavir.Increased triglycerides, Diarrhea, Nausea , taste perversion, |
| Dose Range |
Initial dose 300mg twice daily gradually increased by 100mg twice daily over a period of up to 14 days to a maximum of 600mg twice daily . |
| Drug Interactions | |
| Pregnancy | See lopinavir/ritonavir. |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | SAQUINAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications | Treatment of HIV infection in combination with ritonavir and other antiretroviral agents. |
| Caution | Diarrhea, abdominal discomfort. |
| Dose Range | Adults and children (16 yrs of age and older): 1g twice daily with ritonavir 100mg twice daily , or with lop inavir 400mg/ritonavir 100mg twice daily . Administer within 2 hours after a meal. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | DOLUTEGRAVIR |
| Therapeutic Class | INTEGRASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ELVITEGRAVIR |
| Therapeutic Class | INTEGRASE INHIBITORS |
| Indications | The fixed combination of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir DF) (EVG/c/FTC/TDF) is used for the treatment of human immunodeficiency virus type 1 (HIV More ... |
| Caution | Lactic acidosis and hepatomegaly with steatosis, including fatalities, have been reported with Tenofovir DF in combination with other antiretrovirals; risk is increased in women, obese patients, prolo More ... |
| Dose Range | Elvitegravir is often given with a protease inhibitor, a pharmacokinetic enhancer such as low-dose ritonavir, and at least one other antiretroviral drug; the dose may need to be adjusted to manage drug interactions. |
| Drug Interactions |
Drugs that induce these enzymes may decrease its plasma concentration and it should not be used with strong inducers of CYP3A which include the following: antibacterials (rifampicin) antidepressants More ... |
| Pregnancy | There are no or limited amount of data (less than 300 pregnancy outcomes) from t More ... |
| Breast Feeding | In order to avoid transmission of HIV to the infant it is recommended that HIV i More ... |
| Active Ingredient | RALTEGRAVIR |
| Therapeutic Class | INTEGRASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EFAVIRENZ |
| Therapeutic Class | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIB (NNRTI) |
| Indications |
In combination with other antiretrovirals for the treatment of HIV-1 infection. Efavirenz usually is used in HIV nonnucleoside reverse transcriptase inhibitor-based (NNRTI-based) regimens that includ More ... |
| Caution | Psychiatric disorders, rash, increases in liver enzymes. |
| Dose Range |
Adult: 600mg once daily on an empty stomach preferably at bedtime. Pediatric: 3 years and older and weighing between 10-40kg: 200mg-600mg once daily . |
| Drug Interactions | Efavirenz induces CYP3A and 2B6, and may alter plasma concentrations of drugs metabolized by these enzymes. |
| Pregnancy | Efavirenz may cause fetal harm if administered during the first trimester of pre More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | NEVIRAPINE |
| Therapeutic Class | NNRTI |
| Indications | For use in combination with other antiretroviral agents for the treatment of HIV-1 infection. Nevirap ine reduces maternal to fetal HIV transmission. |
| Caution | Nevirapine is generally well-tolerated. The primary adverse effects are fever, nausea, and headache. However severe and life-threatening skin reactions, toxic epidermal necroly sis and Stevens-Johnson More ... |
| Dose Range | Adult: 200mg once daily for 14 day s, then increased to 200mg twice daily , in ombination with a nucleoside analogue antiretroviral agent. Pediatric: 2 months to 8 y ears: 4mg/kg/day for the first 14 day s followed by 7mg/kg twice daily . 8 y ea |
| Drug Interactions | |
| Pregnancy | The human pregnancy data for nevirapine suggest that the risk for embryo–fetal h More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | ABACAVIR |
| Therapeutic Class | NRTI |
| Indications |
Indicated in combination with other anti-HIV medications for the treatment of HIV-1 for adults and children. |
| Caution | Nausea, vomiting, fatigue, headache, diarrhoea and loss of appetite. Fatal lactic acidosis and severe hep atomegaly with steatosis have been reported. Fatal hypersensitivity reactions include s More ... |
| Dose Range | Adult: Recommended dosing is 300mg orally twice daily with or without food. Pediatric: 3 months - 16 years of age is 8mg/kg orally twice daily (up to a maximum of 300mg twice daily ). Abacavir should be used in combination with other antiretrovirals. |
| Drug Interactions | Alcohol reduces the metabolism of abacavir. |
| Pregnancy | The animal data suggest moderate risk. Although the human pregnancy experience d More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | DIDANOSINE |
| Therapeutic Class | NRTI |
| Indications | A first-line component of a combination antiretroviral therapy regimenfor HIV-1 infected p atients. |
| Caution | Diarrhoea, neuropathy , chills or fever, rash, abdominal pain,weakness, headache and nausea/vomiting. Serious toxicities have included pancreatitis and lactic acidosis (which may be fata More ... |
| Dose Range | Adult: weighing greater than 60kg, 200mg twice daily . Weighing less than or equal to 60kg, 125mg twice daily . Pediatric 8 months and older: 120mg/square meter twice daily . 2 weeks - 8 months: 100mg/square meter twice daily . Take on an empty stomach. |
| Drug Interactions | Coadministration of Didanosine and allopurinol is contraindicated because systemic exposures of Didanosine are increased, which may increase Didanosine-associated toxicity |
| Pregnancy | Reproduction studies have been performed in rats and rabbits at doses up to 12 a More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |